MedinCell Stock Continues Its Midday Rise with a 2.01% Gain
On this Monday, October 20th, the biopharmaceutical company MedinCell's stock shows a mid-session increase of 2.01%, reaching 34.58 euros compared to 33.90 euros at last Friday's close. This rise is part of an upward trend that began last week. The share of capital traded remains moderate at 0.3%, indicating limited activity on the stock in early afternoon.
Current Performance and Market Comparison
MedinCell's stock is up 2.01% at 34.58 euros, while the CAC 40 slightly declines by 0.07% to 8,168.2 points. Over a week, the stock has shown a remarkable performance of 26.02%, bringing the annual gain to 121.1%. This dynamic sharply contrasts with the CAC 40's annual progress of 7.29%. Over three months, the stock has more than doubled with a rise of 116.1%, reflecting a significant resurgence of interest in the stock. The capital turnover remains contained at 0.3% this Monday, indicating measured exchanges during the session. The average volume over twenty sessions stands at about 200,000 shares, a level that the day is unlikely to reach if this trend continues. MedinCell's market capitalization now stands at approximately 1.14 billion euros, with a float representing 61.66% of the capital.
Recent Catalysts and Financial Results
This dynamic week follows the announcement on October 13th, when the stock had jumped 21.06% in a single session to 33.22 euros. The U.S. Food and Drug Administration approved the expanded indication of Uzedy for the treatment of patients with type I bipolar disorder. This regulatory green light triggered a bullish rally that has continued since, with the stock gaining more than a quarter of its value in just a few trading days. The biopharmaceutical licensing company had also published its annual results for 2024-2025 ahead of this movement, showing a revenue of 25.4 million euros, a significant increase.
Technical Analysis and Market Indicators
Technically, the stock is now trading well above its 50-day and 200-day moving averages, which are respectively at 21.59 euros and 16.92 euros. The RSI reaches 87, a particularly high level indicating strong buying pressure. The MACD indicator shows a positive setup with a MACD line at 3.54 points above its signal line at 2.90 points, and the histogram stands at 0.64. Bollinger Bands frame the price between 18.49 euros and 35.50 euros, with the stock now trading near the upper bound. The resistance threshold is set at 33.90 euros, a level surpassed this Monday, while the support is at 18.01 euros. The one-month volatility is at 20.06, reflecting the amplitude of recent movements. The beta of 0.30 indicates a relatively low sensitivity to market variations.
